A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial

• DOI: 10.1186/s13287-021-02246-4
• Publication Date: 2021-04-16T14:34:10Z
• Authors: Yingcai Zhang; Jiebin Zhang; Huimin Yi; Jun Zheng; Jianye Cai; Wenjie Chen; Tongyu Lu; Liang Chen; Cong Du; Jianrong Liu; Jia Yao; Hui Zhao; Guoying Wang; Binsheng Fu; Tong Zhang; Jian Zhang; Genshu Wang; Hua Li; Andy Peng Xiang; Guihua Chen; Shuhong Yi; Qi Zhang; Yang Yang
• Keywords: Graft Rejection; Medicine (General); 0303 health sciences; Research; Graft Survival; QD415-436; Biochemistry; ABO Blood-Group System; Liver Transplantation; 3. Good health; 03 medical and health sciences; R5-920; Treatment Outcome; Severe hepatic failure; Mesenchymal stem cells; Humans; Rituximab; ABO-incompatible liver transplantation

Abstract Background ABO-incompatible liver transplantation (ABO-i LT) has become a rescue therapeutic option for patients with severe hepatic failure. Although the use of rituximab greatly reduces morbidity antibody-mediated rejection (AMR), adverse effects, such as infection and biliary complications, still seriously threaten survival transplant recipients. The aim this study was to evaluate safety feasibility using mesenchymal stem cells (MSCs) replace in ABO-i LT. Methods Twenty-two failure undergoing LT were enrolled randomly divided into two groups: MSC group group. application MSCs incidence allograft rejection, including (AMR) acute cellular (ACR), evaluated both groups at 2-year follow-up period primary endpoints. Recipients graft other postoperative complications compared secondary Results No MSC-related events observed during trial. treatment yielded comparable, if not better, results than decreasing (9.1% vs 27.3%). Inspiringly, those group, rates (0% 45.5%) 81.8%) significantly decreased In addition, there no significant differences recipient between (81.8% 72.7%). Conclusions Our data show that transfusion is comparable AMR prophylaxis following Additionally, indicate are more beneficial prevention may be introduced novel immunosuppressive approach Trial registration registration: chictr.org.cn , ChiCTR2000037732. Registered 31 August 2020- Retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=57074 .